Browse Pharmatica main sections, topics, interview series, and company pages.
Type at least 2 characters to search
Libre Duo FDA Authorisation Through De Novo Pathway
Abbott’s Libre Duo FDA authorisation creates a new Class II device category, combining glucose and ketone monitoring while setting a regulatory path for future devices.
Where Healthcare AI Investment Is Going — And Where It Isn't
The data is out: Two-thirds of AI healthcare startup investment went to just three domains. Insight into clinical leadership, gender inclusivity, and geographical access reveals a sector building for investability… not clinical need.
The AI Bioweapons Risk: We Cannot Afford to Look Away
The risk of AI being used to create a bioweapon is a serious concern for pharma biosecurity after researchers found AI-designed toxins can evade DNA screening. Here’s what you need to know about the AI and bioweapons risk.
AI in Pharma: Hype vs. What Actually Works
Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
No result found for
